A Prospective Single Arm Study to Assess the Efficacy and Safety of Deferasirox 20 mg/kg BID in Transfusion Dependent Thalassemia Patients Inadequately Responding to Current Treatment With Doses >35mg/kg QD
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2017
Price : $35 *
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 15 Jan 2014 According to ClinicalTrials.gov, Status changed from not yet recruiting to withdrawn prior to recruitment.
- 15 Jan 2014 According to ClinicalTrials.gov, Planned End Date changed from 1 Sep 2015 to 1 Feb 2016.